The effect of montelukast in treatment of Pollakiuria

Evaluation the effect of Montelukast on urinary symptoms in children with pollakiuria

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210626051718N1

Enrollment

Registered

2021-07-15

Start date

2021-08-01

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pollakiuria (The daytime urinary frequency syndrome). Frequency of micturition

Interventions

Intervention 1: Intervention group: Montelukast chewable tablets 5 mg/d are prescribed for 14days in 3-15 years old children and 10mg/d for children older than 15 years old.This tablet is produced by

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: All children with pollakiuria aged 3-18 years referred to the pediatric clinic of Amirkabir Hospital in Arak Children with pollakiuria aged 3-18 years who were hospitalized in the pediatric wards of Amirkabir Hospital in Arak History of allergy

Exclusion criteria

Exclusion criteria: Allergiy history to Montelukast

Design outcomes

Primary

Measure	Time frame
Frequency of daytime urination. Timepoint: First at the beginning of the study and then after 14days of receiving treatment. Method of measurement: After 14 days of treatment,the frequency of daytime urination and the exact day which the symptoms had improved will be asked from mothers.Then these information will be noted in check list.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamideh Bakhtiari

Arak University of Medical Sciences

hamide.bakhtiari@gmail.com+98 26 4534 4302

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026